Challenges and risks of using GLP-1 antagonists in treating type 2 diabetes and obesity
DOI:
https://doi.org/10.12775/QS.2024.17.53683Keywords
ozempic, ozempic face, semaglutide, GLP-1, obesityAbstract
Introduction: Ozempic (semaglutide) is a long-acting GLP-1 receptor agonist widely used to treat type II diabetes and obesity. Its mechanism of action includes stimulation of insulin secretion, inhibition of glucagon secretion, and delaying gastric emptying, which leads to lower blood glucose levels and body weight reduction. Despite its therapeutic benefits, the use of Ozempic may cause side effects that affect patients' quality of life and their ability to continue treatment. This article aims to comprehensively analyze side effects associated with using Ozempic to provide a detailed understanding of their development mechanisms and their impact on patient's daily functioning.Material and Methods of Research: The literature was collected through searches in the PubMed and Google Scholar databases and references from the initially retrieved articles. Results: The literature review indicates various potential side effects of liraglutide, including gastrointestinal upset, pancreatitis, and the 'Ozempic face' phenomenon. This phenomenon, characterized by a skeletal facial appearance with deepened wrinkles, may result from the drug's impact on body composition and fat distribution, leading to a loss of subcutaneous fat in the face and a more pronounced appearance of underlying facial structures.Conclusion: Clinical studies highlight the need for continuous patient monitoring by healthcare providers to ensure the safe and effective use of Ozempic. Further education on a healthy lifestyle, diet, and physical activity is necessary to maintain the effects of drug therapy and prevent weight gain after treatment. Additional research on the long-term safety of GLP-1 is also crucial. Physicians should be aware of the potential risks and side effects associated with the use of Ozempic and should educate their patients to enable them to make informed decisions about their treatment.
References
Smits, M. M., & Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in endocrinology, 12, 645563.
https://doi.org/10.3389/fendo.2021.645563
Mahapatra, M.K., Karuppasamy, M. & Sahoo, B.M. Semaglutide, a glucagon-like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord 23, 521–539 (2022).
https://doi.org/10.1007/s11154-021-09699-1
Semaglutyd- medycyna praktyczna (n.d). https://www.mp.pl/pacjent/leki/subst.html?id=5893
Reynolds, M. (2023, June 12). What the scientist who pioneered Weight-Loss drugs wants you to know. WIRED.
https://www.wired.com/story/obesity-drugs-researcher-interview-ozempic-wegovy/
Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management. Journal of Investigative Medicine. 2022;70(1):5-13
https://doi.org/10.1136/jim-2021-001952
Ozempic, European Medicines Agency (n.d). https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic#assessment-history
Tan, Hanna Clementine, et al. “ Efficacy and Safety of Semaglutide for Weight Loss in Obesity without Diabetes: A Systematic Review and Meta-Analysis,” Journal of the ASEAN Federation of Endocrine Societies, vol 37, no.2,25 Nov. 2022, pp.65-72
https://doi.org/10.15605/jafes.037.02.14
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism, 23(3), 754–762. https://doi.org/10.1111/dom.14280
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2017). Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism, 20(3), 610–619. https://doi.org/10.1111/dom.13120
Vecchié, A., Dallegri, F., Carbone, F., Bonaventura, A., Liberale, L., Portincasa, P., Frühbeck, G., & Montecucco, F. (2018). Obesity phenotypes and their paradoxical association with cardiovascular diseases. European journal of internal medicine, 48, 6–17. https://doi.org/10.1016/j.ejim.2017.10.020
Brady SM, Kane MP, Busch RS. GLP-1 agonist use in a patient with an explainable cause of pancreatitis. AACE Clinical Case Reports. 2016; 2(2): e82-e85. https://doi.org/10.4158/EP15658.CR
Xie Z, Yang S, Deng W, Li J, Chen J. Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review. Clin Epidemiol. 2022; 14: 1463-1476.
https://doi.org/10.2147/CLEP.S391819
Shaefer CF Jr, Kushner P, Aguilar R. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015; 127(8): 818-26. https://doi.org/10.1080/00325481.2015.1090295
O'Neill ES, Wiegmann AL, Parrella N, Pittman T, Hood K, Kurlander D. Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future. Plast Reconstr Surg Glob Open. 2024;12(1):e5516. Published 2024 Jan 24.
https://doi.org/10.1097/GOX.0000000000005516 indexed in Pubmed: 38268718
Humphrey CD, Lawrence AC. Implications of ozempic and other semaglutide medications for facial plastic surgeons. Facial Plast Surg. 2023; 39(6): 719-721. https://doi.org/10.1055/a-2148-6321
Wiley KC, Akiyode R, Nunlee-Bland G. Case Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy. Diabetes Spectr. 2015;28(2):121-126. doi:10.2337/diaspect.28.2.121, indexed in Pubmed: 25987811
Habtezion A. Inflammation in acute and chronic pancreatitis. Curr Opin Gastroenterol. 2015; 31(5): 395-9.
https://doi.org/10.1097/MOG.0000000000000195
Zaïmia N, Obeid J, Varrault A, Sabatier J, Broca C, Gilon P, et al. GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function. Cell Rep. 2023; 42(11): 113326.
https://doi.org/10.1016/j.celrep.2023.113326
Bieganek, P., Sadłowski, B., Łukaszewicz, S., Pawłowski, P., Rybak, J., & Kordialik, J. et al. (2024). NEWLY-EMERGING SIDE EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE USAGE ASSOCIATED WITH WEIGHT LOSS TREATMENT. Health Problems of Civilization.
https://doi.org/10.5114/hpc.2024.140505
Chis BA, Fodor D. Acute pancreatitis during GLP-1 receptor agonist treatment. a case report. Clujul Med. 2018; 91(1): 117-119.
https://doi.org/10.15386/cjmed-804
Knapen LM, de Jong RG, Driessen JH, et al. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. Diabetes Obes Metab. 2017;19(3):401-411.
https://doi.org/10.1111/dom.12833, indexed in Pubmed:27883260
.Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014; 348: g2366. https://doi.org/10.1136/bmj.g2366
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022; 24(8): 1553-1564.
https://doi.org/10.1111/dom.14725
Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022; 179(4): 625-641. https://doi.org/10.1111/bph.1567
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021; 325(14): 1414-1425.
https://doi.org/10.1001/jama.2021.3224
Patel F, Gan A, Chang K, Vega KJ. Acute pancreatitis in a patient taking semaglutide. Cureus. 2023; 15(8): e43773.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Agnieszka Głuszczyk, Jakub Plizga, Aleksandra Makłowicz, Ewelina Kopczyńska, Angelika Szpulak, Agata Frańczuk, Michalina Grzelka, Julia Głoskowska, Katarzyna Kuleta, Patrycja Karkos
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 1356
Number of citations: 0